

ESTTA Tracking number: **ESTTA483756**

Filing date: **07/17/2012**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Notice of Opposition

Notice is hereby given that the following party opposes registration of the indicated application.

Opposer Information

Name	Lineagen, Inc.
Granted to Date of previous extension	07/18/2012
Address	423 Wakara Way, Suite 200 Salt Lake City, UT 84107 UNITED STATES

Attorney information	Douglas B. Cannon Fabian Law 215 South State Street, Suite 1200 Salt Lake City, UT 84111-2323 UNITED STATES dcannon@fabianlaw.com Phone:801-323-2227
----------------------	---

Applicant Information

Application No	85454755	Publication date	03/20/2012
Opposition Filing Date	07/17/2012	Opposition Period Ends	07/18/2012
Applicant	AMBRY GENETICS 15 Argonaut Aliso Viejo, CA 92656 UNITED STATES		

Goods/Services Affected by Opposition

Class 044. All goods and services in the class are opposed, namely: Genetic testing for medical purposes; Medical screening; Medical testing for diagnostic or treatment purposes

Grounds for Opposition

The mark is merely descriptive	Trademark Act section 2(e)(1)
Genericness	Trademark Act section 23

Related Proceedings	Opposer will be filing a similar objection to "Diagnostic Odyssey", Serial Number 85454744
---------------------	--

Attachments	Notice of Opposition- Serial No. 85 454,755.pdf (19 pages)(1974528 bytes)
-------------	--

Certificate of Service

The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address record by First Class Mail on this date.

Signature	/Douglas B. Cannon/
Name	Douglas B. Cannon
Date	07/17/2012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Application Serial No. 85/454,755
Published in the Official Gazette on March 20, 2012

LINEAGEN, INC.,

Opposer,

v.

AMBRY GENETICS CORPORATION

Applicant.

Opposition No. _____

TO: Commissioner for Trademarks
P.O. box 1451
Alexandria, Virginia 22313-1451

NOTICE OF OPPOSITION

LINEAGEN, INC., a Delaware corporation with a place of business at 423 Wakara Way, Suite 200, Salt Lake City, Utah 84108 (hereinafter "Opposer") believes that it will be damaged by registration of the designation AVOID THE DIAGNOSTIC ODYSSEY for "Genetic testing for medical purposes; Medical screening; Medical testing for diagnostic or treatment purposes" in International Class 044 as shown in Application Serial No. 85/454,755 filed on October 24, 2011 by AMBRY GENETICS CORPORATION, with a place of business at 15 Argonaut, Aliso Viejo, California, 92656 (hereafter "Applicant") ("the "755 application") and hereby opposes the same.

The grounds for this Opposition are as follows:

1. Opposer is an innovative diagnostics company focused on complex, genetically linked disorders such as autism and developmental delay, multiple sclerosis (MS), and chronic obstructive pulmonary disease (COPD), where timely genetic insights can significantly improve outcomes.

2. Opposer is the owner of all right, title and interested in the United States to FirstStep (Serial No. 85/095,157) and FirstStep^{Dx} (Reg. 4,039.525) trademarks (“Opposer’s Marks”) for medical testing services, namely, molecular and genetic testing for disorders of childhood development, in Class 44 (U.S. CLS. 100 and 101) and for medical specimen collection and transportation kit comprised of blood collection tubes, foam container for tubes, absorbent pad, biohazard bag, marker, labels, mail packaging form and instructions for molecular and genetic testing for disorders of childhood development, in Class 10 (U.S. CLS 026, 039 and 044) (“Opposer’s Goods”). Copies of the registration information from the Patent and Trademark Office website are attached as Exhibit A.

3. Opposer’s Goods and Services have been developed with the specific intention of helping physicians, patients, and families navigate the odyssey of diagnosing and evaluating children with autism spectrum disorder (ASD) and related forms of developmental delay more efficiently.

4. Opposer has used the term “diagnostic odyssey” to generically describe the process and time period taken by patients and/or their parents or guardians to secure an accurate diagnosis of the patient’s medical condition such as autism spectrum disorder, developmental delay or multiple sclerosis.

5. Opposer has continuously and extensively used the term “diagnostic odyssey” when discussing Opposer’s Goods and Services. Opposer’s use of the phrase “diagnostic odyssey” has been used in Opposer’s website, marketing material, and verbal presentations and discussions. Examples of Opposer’s use of “diagnostic odyssey” are attached as Exhibit B.

6. Opposer is well and favorably known through the United States and has built up valuable interest, goodwill and reputation in its Goods and Services.

7. Applicant’s Goods are described in the ‘744 application as “Genetic testing for medical purpose; Medical screening; Medical testing for diagnostic or treatment purposes.” Such goods are similar to Opposer’s Goods, such that there is an increased likelihood that Applicant’s goods are or will be sold through the same channels and targeted to the same consumers as Opposer’s Goods.

8. Applicant seeks to register the mark AVOID THE DIAGNOSTIC ODYSSEY exclusively to describe Applicant’s Goods. As a result, Applicant’s exclusive use and registration of the Applicant’s ‘744 application in connection with Applicant’s Goods may cause Applicant to seek to bar Opposer from generically using the term “diagnostic odyssey” or similar variations in the future. Such action would cause damage to Opposer.

9. The use of the phrase, “diagnostic odyssey,” relating to genetic testing, autism developmental delay, mental retardation, intellectual disability, and other disorders of childhood development is currently in widespread use and has been for many years. Therefore,

the mark AVOID THE DIAGNOSTIC ODYSSEY should be deemed “generic” and hence incapable of functioning as a trademark or serving a source-identifying function.

WHEREFORE, Opposer prays that this Opposition be sustained and the application Serial No. 85/454,755 sought by Applicant be refused.

Dated this 16th day of July, 2012.

FABIAN & CLENDENIN
Attorneys for Opposer

By: 

Douglas B. Cannon

FABIAN & CLENDENIN, P.C.
215 South State Street, Suite 1200
Salt Lake City, UT 84111-2323
office (801) 531-8900
fax (801) 531-1716
dcannon@fabianlaw.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Application Serial No. 85/454,755
Published in the Official Gazette on March 20, 2012

LINEAGEN, INC.,

Opposer,

v.

AMBRY GENETICS CORPORATION

Applicant.

Opposition No. _____

Certificate of Service

The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address record by First Class Mail on this date.

Lynne M.J. Boisineau
McDermott, Will & Emery LLP
4 Park Plaza, Suite 1700
Irvine, CA 92614-2559
Appointed Attorney

Ambry Genetics Corporation California
15 Argonaut
Aliso Viejo, CA 92656
Applicant

Dated this 16th day of July, 2012.

FABIAN & CLENDENIN
Attorneys for Opposer

By: _____



Douglas B. Cannon

Exhibit A

Thank you for your request. Here are the latest results from the TARR web server.

This page was generated by the TARR system on 2012-07-16 12:45:04 ET

Serial Number: 85095105 Assignment Information Trademark Document Retrieval

Registration Number: 4039525

Mark

FIRSTSTEPDX

(words only): FIRSTSTEPDX

Standard Character claim: Yes

Current Status: Registered. The registration date is used to determine when post-registration maintenance documents are due.

Date of Status: 2011-10-11

Filing Date: 2010-07-28

Transformed into a National Application: No

Registration Date: 2011-10-11

Register: Principal

Law Office Assigned: LAW OFFICE 104

If you are the applicant or applicant's attorney and have questions about this file, please contact the Trademark Assistance Center at TrademarkAssistanceCenter@uspto.gov

Current Location: 650 -Publication And Issue Section

Date In Location: 2011-09-07

LAST APPLICANT(S)/OWNER(S) OF RECORD

1. LineaGen, Inc.

Address:

LineaGen, Inc.
Suite 200 423 Wakara Way
Salt Lake City, UT 84108
United States

Legal Entity Type: Corporation

State or Country of Incorporation: Delaware

Phone Number: 801-931-6200

GOODS AND/OR SERVICES

International Class: 010

Class Status: Active

Medical specimen collection and transportation kit comprised of blood collection tubes, foam container for tubes, absorbent pad, biohazard bag, marker, labels, mail packaging, forms and instructions, for molecular and genetic testing for disorders of childhood development

Basis: 1(a)

First Use Date: 2011-01-31

First Use in Commerce Date: 2011-01-31

International Class: 044

Class Status: Active

Medical testing services, namely, molecular and genetic testing for disorders of childhood development

Basis: 1(a)

First Use Date: 2011-01-31

First Use in Commerce Date: 2011-01-31

ADDITIONAL INFORMATION

(NOT AVAILABLE)

MADRID PROTOCOL INFORMATION

(NOT AVAILABLE)

PROSECUTION HISTORY

NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.

2011-10-11 - Registered - Principal Register

2011-09-08 - Notice Of Acceptance Of Statement Of Use E-Mailed
2011-09-07 - Law Office Registration Review Completed
2011-09-01 - Allowed for Registration - Principal Register (SOU accepted)
2011-08-23 - Statement Of Use Processing Complete
2011-08-05 - Use Amendment Filed
2011-08-22 - Case Assigned To Intent To Use Paralegal
2011-08-05 - TEAS Statement of Use Received
2011-05-10 - NOA E-Mailed - SOU Required From Applicant
2011-03-15 - Official Gazette Publication Confirmation E-Mailed
2011-03-15 - Published for opposition
2011-02-10 - Law Office Publication Review Completed
2011-02-04 - Approved For Pub - Principal Register
2011-02-04 - Examiner's Amendment Entered
2011-02-04 - Notification Of Examiners Amendment E-Mailed
2011-02-04 - EXAMINERS AMENDMENT E-MAILED
2011-02-04 - Examiners Amendment -Written
2011-01-31 - Previous Allowance Count Withdrawn
2011-01-07 - Withdrawn From Pub - Og Review Query
2010-12-27 - Law Office Publication Review Completed
2010-12-27 - Assigned To LIE
2010-12-03 - Approved For Pub - Principal Register
2010-12-03 - Examiner's Amendment Entered
2010-12-03 - Notification Of Examiners Amendment E-Mailed
2010-12-03 - EXAMINERS AMENDMENT E-MAILED
2010-12-03 - Examiners Amendment -Written

2010-11-10 - Notification Of Non-Final Action E-Mailed
2010-11-10 - Non-final action e-mailed
2010-11-10 - Non-Final Action Written
2010-11-10 - Assigned To Examiner
2010-08-03 - Notice Of Pseudo Mark Mailed
2010-08-02 - New Application Office Supplied Data Entered In Tram
2010-07-31 - New Application Entered In Tram

ATTORNEY/CORRESPONDENT INFORMATION

Attorney of Record

Douglas B. Cannon

Correspondent

DOUGLAS B. CANNON
FABIAN & CLENDENIN
215 S STATE ST STE 1200
SALT LAKE CITY, UT 84111-2323
Phone Number: 801-323-2227
Fax Number: 801-531-1716

Thank you for your request. Here are the latest results from the TARR web server.

This page was generated by the TARR system on 2012-07-16 12:46:05 ET

Serial Number: 85095157 Assignment Information Trademark Document Retrieval

Registration Number:(NOT AVAILABLE)

Mark

FIRSTSTEP

(words only): FIRSTSTEP

Standard Character claim: Yes

Current Status: A second request for extension of time to file a Statement of Use has been granted.

Date of Status: 2012-05-03

Filing Date: 2010-07-28

The Notice of Allowance Date is: 2011-05-10

Transformed into a National Application: No

Registration Date: (DATE NOT AVAILABLE)

Register: Principal

Law Office Assigned: LAW OFFICE 104

Attorney Assigned:
MISTER KATINA SHAY

Current Location: 700 -Intent To Use Section

Date In Location: 2012-05-02

LAST APPLICANT(S)/OWNER(S) OF RECORD

1. LineaGen, Inc.

Address:

LineaGen, Inc.
Suite 200 423 Wakara Way
Salt Lake City, UT 84108
United States

Legal Entity Type: Corporation

State or Country of Incorporation: Delaware

Phone Number: 801-931-6200

GOODS AND/OR SERVICES

International Class: 010

Class Status: Active

Medical specimen collection and transportation kit comprised of blood collection tubes, foam container for tubes, absorbent pad, biohazard bag, marker, labels, mail packaging, forms and instructions, for molecular and genetic testing for disorders of childhood development

Basis: 1(b)

First Use Date: (DATE NOT AVAILABLE)

First Use in Commerce Date: (DATE NOT AVAILABLE)

International Class: 044

Class Status: Active

Medical testing services, namely, molecular and genetic testing for disorders of childhood development

Basis: 1(b)

First Use Date: (DATE NOT AVAILABLE)

First Use in Commerce Date: (DATE NOT AVAILABLE)

ADDITIONAL INFORMATION

(NOT AVAILABLE)

MADRID PROTOCOL INFORMATION

(NOT AVAILABLE)

PROSECUTION HISTORY

NOTE: To view any document referenced below, click on the link to "Trademark Document Retrieval" shown near the top of this page.

2012-05-04 - Notice Of Approval Of Extension Request E-Mailed

2012-05-03 - Extension 2 granted
2012-04-06 - Extension 2 filed
2012-05-02 - Case Assigned To Intent To Use Paralegal
2012-04-06 - TEAS Extension Received
2011-11-01 - Notice Of Approval Of Extension Request E-Mailed
2011-10-28 - Extension 1 granted
2011-10-28 - Extension 1 filed
2011-10-28 - TEAS Extension Received
2011-05-10 - NOA E-Mailed - SOU Required From Applicant
2011-03-15 - Official Gazette Publication Confirmation E-Mailed
2011-03-15 - Published for opposition
2011-02-10 - Law Office Publication Review Completed
2011-02-04 - Approved For Pub - Principal Register
2011-02-04 - Examiner's Amendment Entered
2011-02-04 - Notification Of Examiners Amendment E-Mailed
2011-02-04 - EXAMINERS AMENDMENT E-MAILED
2011-02-04 - Examiners Amendment -Written
2011-01-31 - Previous Allowance Count Withdrawn
2011-01-07 - Withdrawn From Pub - Og Review Query
2010-12-27 - Law Office Publication Review Completed
2010-12-27 - Assigned To LIE
2010-12-03 - Approved For Pub - Principal Register
2010-12-03 - Examiner's Amendment Entered
2010-12-03 - Notification Of Examiners Amendment E-Mailed
2010-12-03 - EXAMINERS AMENDMENT E-MAILED

2010-12-03 - Examiners Amendment -Written
2010-11-10 - Notification Of Non-Final Action E-Mailed
2010-11-10 - Non-final action e-mailed
2010-11-10 - Non-Final Action Written
2010-11-10 - Assigned To Examiner
2010-08-03 - Notice Of Pseudo Mark Mailed
2010-08-02 - New Application Office Supplied Data Entered In Tram
2010-07-31 - New Application Entered In Tram

ATTORNEY/CORRESPONDENT INFORMATION

Attorney of Record

Douglas B. Cannon

Correspondent

DOUGLAS B. CANNON
FABIAN & CLENDENIN
215 S STATE ST STE 1200
SALT LAKE CITY, UT 84111-2323
Phone Number: 801-323-2227
Fax Number: 801-531-1716

Exhibit B

About Lineagen

About Lineagen

[History](#)

[Values](#)

[Management Team](#)

[Clinical Services Team](#)

[Board of Directors](#)

[Investors](#)

At Lineagen, our mission is to accelerate and enhance the diagnostic evaluation of medical conditions so that the best possible outcomes can be achieved for patients and their families. Our first commercial offering, FirstStep[®], provides physicians with a fully integrated genetic testing, counseling, and developmental screening service to aid in the clinical evaluation of children with autism spectrum disorder (ASD) or other forms of developmental delay. In addition to our deep commitment to autism, we have ongoing scientific programs in the areas of multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD).

Changing the Diagnostic Odyssey

In conditions such as ASD, critical time, sometimes years, can be lost during the diagnostic odyssey, which spans earliest concern to clinical action.

At Lineagen we firmly believe that we can change this for the better. Access to recommended genetic testing for individuals with autism and developmental delay should have no waiting list since it is available today - we believe that genetics can provide healthcare professionals with timely and objective information to aid in the clinical diagnostic evaluation of children with ASD or other forms of developmental delay. And we believe that personalized counseling will help patients, as well as their physicians, to make better and more informed decisions.

Forging Lasting Relationships

Our core values center on the belief that we will achieve our goals only through earning and maintaining long term, trust-based relationships with the patients, families, and healthcare professionals we serve. Our services focus on delivering quality and sound science, along with hope, compassion, and personal assistance to our customers as individuals.

We are compelled to deliver our best services as soon as practicable. The entire Lineagen team looks forward to serving you and exceeding your expectations.



A personal welcome to **LINEAGEN**

"I am privileged to introduce you to Lineagen.

Our goal is to help physicians and their patients by accelerating and enhancing the diagnostic evaluation of medical conditions. By enabling earlier and more personalized intervention, we aim to improve the lives of patients and their families.

We look forward to partnering with you as we work to provide exceptional, personalized service."



Michael S. Paul, Ph.D., President & CEO, Lineagen, Inc.

Lineagen looks forward to serving you.

Achieving the best possible outcomes

At Lineagen our focus is to enhance and accelerate the diagnostic evaluation of medical conditions. Our current services are designed to help physicians and families better assess children with autism spectrum disorder (ASD) and developmental delay (DD).

Your Trust in Lineagen

Our core values center on the belief that we will achieve our goals only through establishing and maintaining trust relationships with our customers, and by delivering hope and compassion. Our support team consists of physicians, pediatric nurses, certified genetic counselors, and a responsive customer service team all committed to help you get the answers you need.

Changing the Diagnostic Odyssey of ASD

With conditions such as ASD, time truly matters. Recent clinical studies have reported that earlier diagnosis can lead to earlier intervention, resulting in better outcomes for children with ASD. At Lineagen, our mission is to provide healthcare professionals with innovative tools and services to support this earlier diagnosis. ASD has a strong genetic component, with the condition reported to be at least 70% heritable. To address this piece of the puzzle, we offer personalized genetic counseling and support for both physicians and families to encourage more informed and timely treatment decisions. Our ongoing support for healthcare professionals includes improved access to the latest information and tools to support the evaluation of children with ASD and DD.

Setting a new standard

We have invested in several major initiatives for ASD, including the launch of our first genetic testing service, **FirstStep^{DX}**.

Lineagen's **FirstStep^{DX}** genetic service is comprised of genetic testing, genetic counseling, and comprehensive reporting. **FirstStep^{DX}** contains two genetic tests, chromosomal microarray (CMA) and fragile X analyses. Licensed and Certified genetic counselors are available for pre- and post-test consultation services for both physicians and families to ensure a better understanding of these tests and the results. The counselors also generate comprehensive reports that include diagrams, references, and a glossary.

Recent publications in scientific and medical journals, including *Pediatrics*[®] and *The American Journal of Human Genetics*[®] state that CMA testing should be offered as a first-tier genetic test for patients with ASD, unexplained DD, or intellectual disability (ID). In fact, the American College of Medical Genetics Practice Guidelines recommend CMA as part of the clinical evaluation of children with ASD, DD, and ID. The science used in **FirstStep^{DX}** represents the best-in-class tool for the genetic evaluation of these conditions, using technology that can identify hundreds of genetic markers known to be associated with disorders of childhood development.

With roots in fundamental research, Lineagen continues to invest heavily in genetic test development. For example, Lineagen and The Children's Hospital of Philadelphia have collaborated to initiate one of the largest clinical studies on ASD genetics ever undertaken. Our goal is to continue to provide best-in-class tools to help better understand the genetic basis of ASD.

The entire Lineagen team looks forward to serving you and exceeding your expectations. Please do not hesitate to contact us with any questions you may have. We are here to help and we look forward to hearing from you.

Sincerely,

A handwritten signature in black ink that reads "Michael S. Paul". The signature is written in a cursive, professional style.



Lineagen, Inc.,
423 Wakara Way,
Salt Lake City, Utah 84108, USA

REV. 021011

For more information about Lineagen
Call toll-free at 888-888-OPEN (6736) or visit www.lineagen.com

Programs

- About Eccles
 - Undergraduate
 - Full-Time MBA
 - Executive MBA
 - Professional MBA
 - MBA Dual Degrees
 - Master of Accounting
 - Master of Science in Finance
 - Master of Science in Information Systems
 - Master of Real Estate Development
 - Master of Healthcare Administration
 - PhD
 - Executive Education

Essentials

- Academic Departments
- Professional Centers
- Faculty & Research
- News Center
 - Calendar
 - Directory

The Network

- Alumni
- Parents
- Recruiters
- Military

Stay Connected



Lineagen Launches Genetic Testing and Counseling

Press Release



SALT LAKE CITY—Lineagen announces the launch of its FirstStepDx integrated genetic testing and counseling service to assist pediatricians and family physicians with the earlier, more accurate diagnostic evaluation of autism spectrum disorders (ASD) and developmental delay (DD). FirstStepDx testing identifies certain genetic factors associated with ASD and DD.

Early diagnostic evaluation of children with ASD is critical so that they can receive the earliest possible proactive intervention. Recent clinical data has shown that behavioral intervention therapy is effective in treating the symptoms of ASD in children as young as 18 months of age. The average age of diagnosis in the United States is currently between 4 and 5 years old, resulting in the loss of valuable time for treating these children.

FirstStepDx integrates the most advanced and comprehensive genetic testing technology with pre- and post testing-consultation, provided by Lineagen's certified genetic counselors. The American College of Medical Genetics now recommends the technology used in FirstStepDx's genetic testing service as standard of care for apparent DD, ASD, and other conditions of childhood development.

"We created FirstStepDx to help community-based pediatricians and families confront the often overwhelming challenges associated with the evaluation of children with autism spectrum disorders and apparent developmental delay. Our service is focused entirely on shortening their diagnostic odyssey," said Michael Paul, Ph.D., CEO of Lineagen. "FirstStepDx is at the forefront of a new personalized approach to healthcare delivery and is the first specialist service that empowers community pediatricians with recommended standard of care genetic testing and best-in-class counseling service."

The diagnosis of ASD and other conditions of childhood development can be slow, expensive, and frustrating for all involved. FirstStepDx addresses the backlogs and long waiting periods often associated with the evaluation of developmental disorders, by providing to the community physician the innovative molecular diagnostic tests and genetic counseling services that have been previously limited to specialist urban medical centers.

"Parents are often desperate to find an answer or a reason for their child's unique developmental problems," said Dr. Miguel Knochel, FAAP of the Payson Pediatrics Canyon View Medical Group in Utah. "I have used FirstStepDx with a number of patients where ASD is suspected or confirmed. In all of these cases, Lineagen's service has proven to be extremely useful in the evaluation process. The FirstStepDx genetic test result can be the final piece of the puzzle, helping me with the clinical management of my patients. Based on these experiences, I will offer FirstStepDx right away to all my patients with potential clinical features of ASD or other developmental delays, especially for children with distinctive facial features, minor anomalies, or a family history of ASD."

"Lineagen treats us as family and has helped us throughout this process and experience," said Brigitte Kraci of Payson, Utah, the mother of a child with ASD-like symptoms whose diagnosis of Angelman syndrome was confirmed by FirstStepDx. "I can ask them anything and they help me to understand all I need to know. Lineagen changed our lives. We can now give our son the help and support he deserves and needs."

The Critical Importance of Diagnosing Autism Earlier

Autism spectrum disorder, the fastest-growing developmental disorder in the United States, currently affects an estimated 1 in every 110 children, including up to 1 in 58 boys. A growing body of research, including recent major studies such as "The Early Start Denver Model" in Pediatrics, indicates that early diagnosis coupled with intensive behavioral intervention can make a profound positive difference to the lives of children with ASD and their families. Behavioral therapy has been shown to improve IQ, language and social skills, and has the ability to "mainstream" children into standard school systems.

Key Scientific Collaborations

Physicians ordering FirstStepDx also benefit from Lineagen's ongoing research into genetic factors related to ASD. Close scientific collaboration with two global leaders in genetic research is helping to identify new genetic markers for ASD. The first, the University of Utah, has identified more genes causative for diseases than any other institution in the world, and was one of the early participating organizations in the Human Genome Project. The second collaborator, The Children's Hospital of Philadelphia (CHOP), is widely recognized as one of the world's preeminent pediatric institutes and a leader in ASD research. Lineagen is working closely with both partners to commercialize novel genetic markers associated with ASD that will in turn increase the diagnostic yield of the FirstStepDx genetic test.

Ordering FirstStepDx

The full complement of FirstStepDx services is currently provided through physicians in California, Colorado, Connecticut, Oklahoma and Utah. Throughout 2011, Lineagen plans to make FirstStepDx available to physicians in a growing number of locations throughout the United States. For more information and support please visit the Lineagen website or call 1-888-888-OPEN (6736).

Online Press Room

The Lineagen online press room is available at <http://www.lineagen.com/NewsPressReleases/Press-Materials.aspx>, and includes downloadable press presentation, company and product information, and high-resolution images.

About Lineagen

Lineagen, based in Salt Lake City, sells innovative diagnostic and consultative healthcare services for autism spectrum disorders (ASD) to physicians, combining high-value genetic testing with comprehensive, personalized consultative services.

Lineagen is strongly differentiated through its focus on specific complex diseases and disorders with demonstrated genetic association: ASD, multiple sclerosis (MS), and chronic obstructive pulmonary disorder (COPD). This specialization enables the company to combine powerful insight into clinical diagnostic pathways with strong proprietary and in-licensed research data, resulting in earlier, more personalized intervention and management for conditions where genetic susceptibility matters. Lineagen addresses a

large, unmet, and growing need for expert genetic testing and counseling services designed to support community physicians and families.

 [SHARE](#)  [Printer-friendly version](#)

©2007 THE UNIVERSITY OF UTAH 1655 EAST CAMPUS CENTER DRIVE SPENCER FOX ECCLES BUSINESS BUILDING SALT LAKE CITY UT 84112
[THE UNIVERSITY OF UTAH](#) [CONTACT US](#) [WEBMASTER](#) [DISCLAIMER](#) [PRIVACY](#) [LOGIN](#)
